Literature DB >> 2416204

Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog.

E Masini, J Planchenault, F Pezziardi, P Gautier, J P Gagnol.   

Abstract

The solvent of commercial amiodarone (Polysorbate 80) has been reported to produce haemodynamic responses in humans and in dogs similar to those produced by histamine infusion. We therefore evaluated the correlation between hypotension induced by the solvent of amiodarone and its histamine-releasing properties in the awake dog. The solvent of amiodarone administered to a dog, over 5 min in a dose of 10 mg/kg of Polysorbate 80, produced severe hypotension after the first administration; the second injection (24 h later) caused fewer hypotensive effects. Histamine release in the peripheral tissues was demonstrated by a marked increase in plasma histamine concentrations, with the maximum value 10 min after the solvent administration. H1- and H2-receptor blockade with mepyramine (5 mg/kg) and cimetidine (10 mg/kg) significantly reduced the cardiovascular effects of the solvent. Isolated peritoneal mast cells from rats also released histamine in response to Polysorbate 80. These studies show that Polysorbate 80 releases histamine both in vitro and in isolated mast cells from rats and in vivo in the dog, and that the plasma concentrations are correlated with the haemodynamic responses.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2416204     DOI: 10.1007/bf01983649

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  34 in total

1.  Alterations in the circulatory system of anaesthesized dogs following administration of histamine and histamine H1- and H2-Receptor antagonists in relation to plasma histamine levels.

Authors:  M Thermann; W Lorenz; A Schmal; F Schingale; P Dormann; H Hamelmann
Journal:  Agents Actions       Date:  1975-12

2.  Liberation of histamine from the skeletal muscle by curare.

Authors:  M Alam; G V Anrep; G S Barsoum; M Talaat; E Wieninger
Journal:  J Physiol       Date:  1939-02-14       Impact factor: 5.182

Review 3.  Anaphylactoid reactions to i.v. substances.

Authors:  J Watkins
Journal:  Br J Anaesth       Date:  1979-01       Impact factor: 9.166

4.  Histamine receptors in the human heart.

Authors:  R Ginsburg; M R Bristow; E B Stinson; D C Harrison
Journal:  Life Sci       Date:  1980-06-30       Impact factor: 5.037

5.  Re-entrant ventricular arrhythmias in the late myocardial infarction period. 2. Patterns of initiation and termination of re-entry.

Authors:  N El-Sherif; R R Hope; B J Scherlag; R Lazzara
Journal:  Circulation       Date:  1977-05       Impact factor: 29.690

6.  Definition and classification of the histamine-release response to drugs in anaesthesia and surgery: studies in the conscious human subject.

Authors:  W Lorenz; A Doenicke; B Schöning; C Ohmann; B Grote; E Neugebauer
Journal:  Klin Wochenschr       Date:  1982-09-01

7.  [Liberation of histamine by anaesthetics (author's transl)].

Authors:  C Meyer-Burgdorff; G Seidel; I Wolf
Journal:  Anaesthesist       Date:  1976-01       Impact factor: 1.041

8.  Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: analysis of various components in cremophor El and development of a compound with reduced toxicity.

Authors:  W Lorenz; A Schmal; H Schult; S Lang; C Ohmann; D Weber; B Kapp; L Lüben; A Doenicke
Journal:  Agents Actions       Date:  1982-04

9.  Hypotensive action of commercial intravenous amiodarone and polysorbate 80 in dogs.

Authors:  W B Gough; R H Zeiler; P Barreca; N El-Sherif
Journal:  J Cardiovasc Pharmacol       Date:  1982 May-Jun       Impact factor: 3.105

10.  Re-entrant ventricular arrhythmias in the late myocardial infarction period. 1. Conduction characteristics in the infarction zone.

Authors:  N El-Sherif; B J Scherlag; R Lazzara; R R Hope
Journal:  Circulation       Date:  1977-05       Impact factor: 29.690

View more
  21 in total

1.  Protective effect of relaxin in cardiac anaphylaxis: involvement of the nitric oxide pathway.

Authors:  E Masini; G Zagli; J F Ndisang; M Solazzo; P F Mannaioni; D Bani
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

Review 2.  Principles of safety pharmacology.

Authors:  M K Pugsley; S Authier; M J Curtis
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

Review 3.  Pharmaceutical excipients. Adverse effects associated with 'inactive' ingredients in drug products (Part II).

Authors:  L K Golightly; S S Smolinske; M L Bennett; E W Sutherland; B H Rumack
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun

Review 4.  Nanomedicines: From Bench to Bedside and Beyond.

Authors:  Henry Havel; Gregory Finch; Pamela Strode; Marc Wolfgang; Stephen Zale; Iulian Bobe; Hagop Youssoufian; Matthew Peterson; Maggie Liu
Journal:  AAPS J       Date:  2016-08-01       Impact factor: 4.009

5.  Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs.

Authors:  Kenneth M Rassnick; Josephia R Muindi; Candace S Johnson; Dennis B Bailey; Donald L Trump
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-21       Impact factor: 3.333

Review 6. 

Authors:  J P Nolan; C D Deakin; J Soar; B W Böttiger; G Smith; M Baubin; B Dirks; V Wenzel
Journal:  Notf Rett Med       Date:  2006-02-01       Impact factor: 0.826

Review 7.  Immediate Drug Hypersensitivity.

Authors:  Paige G Wickner; David Hong
Journal:  Curr Allergy Asthma Rep       Date:  2016-07       Impact factor: 4.806

8.  Clinical and pharmacokinetic overview of parenteral etoposide phosphate.

Authors:  L P Schacter; L N Igwemezie; M Seyedsadr; E Morgenthien; J Randolph; E Albert; P Santabárbara
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors.

Authors:  Kenneth M Rassnick; Josephia R Muindi; Candace S Johnson; Cheryl E Balkman; Nithya Ramnath; Wei-Dong Yu; Kristie L Engler; Rodney L Page; Donald L Trump
Journal:  Cancer Chemother Pharmacol       Date:  2008-02-02       Impact factor: 3.333

10.  In vitro cytotoxicity of novel pro-apoptotic agent DM-PIT-1 in PEG-PE-based micelles alone and in combination with TRAIL.

Authors:  Igor Skidan; Benchun Miao; Ritesh V Thekkedath; Parita Dholakia; Alexei Degterev; Vladimir Torchilin
Journal:  Drug Deliv       Date:  2009-01       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.